<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03872284</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL18_0749</org_study_id>
    <secondary_id>2019-A00684-53</secondary_id>
    <nct_id>NCT03872284</nct_id>
  </id_info>
  <brief_title>Neuro-ophthalmology and Autoimmune Encephalitis (NODE)</brief_title>
  <acronym>NODE</acronym>
  <official_title>Study of Neuro-ophthalmology Disorders in Autoimmune Encephalitis (NODE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autoimmune encephalitis represents a group of rare and heterogeneous neurological disorders.
      Pathophysiological mechanisms in these diseases are still unknown. Recently, oculomotor and
      neurovisual disorders have been described. Cerebral areas and neuronal networks associated
      with these abnormalities are well described. The investigator proposes to study and describe
      such neuro-ophthalmological disorders in a prospective cohort of patients with a autoimmune
      encephalitis, to better understand the pathophysiological basis of this neurological
      condition.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2020</start_date>
  <completion_date type="Anticipated">January 24, 2027</completion_date>
  <primary_completion_date type="Anticipated">January 24, 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients presenting a neuro-ophthalmological abnormality.</measure>
    <time_frame>Day 0</time_frame>
    <description>A neuro-ophthalmological disorder is defined as an abnormality in the oculo-motor movement recording or/and the presence of a neurovisual impairment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients presenting neuro-ophthalmological abnormality.</measure>
    <time_frame>At 6 months if an abnormality is found</time_frame>
    <description>A neuro-ophthalmological disorder is defined as an abnormality in the oculo-motor movement recording or/and the presence of a neurovisual impairment.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Autoimmune Encephalitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Patients in the study group have a diagnosis of autoimmune encephalitis, are 18 to 70 years old, and have no significant comorbidity such as psychiatric, neurological conditions and able to understand the aim of this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>oculomotor movement recordings, neurovisual assessment</intervention_name>
    <description>Each participant will have a neurovisual assessment and an oculomotor movement recording with an eye tracker (infra red cameras).</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Men and women 18 to 70 years old diagnosed with autoimmune encephalitis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of autoimmune encephalitis

          -  With or without pathological antibody

          -  Aged from 18 to 70 years old

          -  Able to understand the aims and methods of this project

          -  Non opposed to the participation of this study

        Exclusion Criteria:

          -  Other neurological, psychiatric or systemic conditions, which could induce
             neuro-ophthalmological signs Cognitive impairment, which is not linked to autoimmune
             encephalitis

          -  Ophthalmological condition, which could modify the interpretation of
             neuro-ophthalmological data Inability to remain seated

          -  Pregnancy or breast feeding

          -  Adults under guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caroline Tilikete, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of neuro-ophthalmology, Pierre Wertheimer university hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline Tilikete, Prof.</last_name>
    <phone>4 72 11 93 84</phone>
    <phone_ext>33</phone_ext>
    <email>caroline.tilikete@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline TILIKETE, MD</last_name>
      <email>caroline.tilikete@inserm.fr</email>
    </contact>
    <investigator>
      <last_name>Caroline TILIKETE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aude METZGER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2019</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Hashimoto Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

